Fintel reports that on April 21, 2025, Wolfe Research upgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from ...

Intellia Therapeutics has said it will reduce its ... its resources behind two priority drug candidates. The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer ...

Intellia Therapeutics, Inc. NTLA is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin ...

A class action lawsuit was filed against Intellia Therapeutics Inc. (NTLA) by Levi & Korsinsky on February 11, 2025. The ...

Intellia Therapeutics, Inc, a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, announced the first patient has been dosed in MAGNITUDE-2, a ...

March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today ...

Despite Intellia Therapeutics reducing its workforce and reprioritizing its pipeline in only advancing in-vivo CRISPR NTLA-2002 and in-vivo CRISPR nex-z, it has several key catalysts for investors ...

April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...

Biomedical Research leads at USD 1.5 billion, supporting genetic discovery and translational research.

March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies ...